HilleVax (HLVX) Competitors $2.06 -0.01 (-0.48%) Closing price 04:00 PM EasternExtended Trading$2.06 +0.00 (+0.24%) As of 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock HLVX vs. TECX, EOLS, CMPS, PRTA, REPL, ARCT, RGNX, MBX, ATXS, and YMABShould you be buying HilleVax stock or one of its competitors? The main competitors of HilleVax include Tectonic Therapeutic (TECX), Evolus (EOLS), COMPASS Pathways (CMPS), Prothena (PRTA), Replimune Group (REPL), Arcturus Therapeutics (ARCT), REGENXBIO (RGNX), MBX Biosciences (MBX), Astria Therapeutics (ATXS), and Y-mAbs Therapeutics (YMAB). These companies are all part of the "pharmaceutical products" industry. HilleVax vs. Its Competitors Tectonic Therapeutic Evolus COMPASS Pathways Prothena Replimune Group Arcturus Therapeutics REGENXBIO MBX Biosciences Astria Therapeutics Y-mAbs Therapeutics Tectonic Therapeutic (NASDAQ:TECX) and HilleVax (NASDAQ:HLVX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations. Which has more risk & volatility, TECX or HLVX? Tectonic Therapeutic has a beta of 3.27, meaning that its share price is 227% more volatile than the S&P 500. Comparatively, HilleVax has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500. Do analysts prefer TECX or HLVX? Tectonic Therapeutic presently has a consensus price target of $80.33, suggesting a potential upside of 206.85%. HilleVax has a consensus price target of $2.00, suggesting a potential downside of 2.91%. Given Tectonic Therapeutic's stronger consensus rating and higher possible upside, equities analysts plainly believe Tectonic Therapeutic is more favorable than HilleVax.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tectonic Therapeutic 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17HilleVax 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has better earnings and valuation, TECX or HLVX? Tectonic Therapeutic is trading at a lower price-to-earnings ratio than HilleVax, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTectonic TherapeuticN/AN/A-$57.98M-$4.04-6.48HilleVaxN/AN/A-$147.27M-$1.43-1.44 Is TECX or HLVX more profitable? Tectonic Therapeutic's return on equity of -30.13% beat HilleVax's return on equity.Company Net Margins Return on Equity Return on Assets Tectonic TherapeuticN/A -30.13% -28.33% HilleVax N/A -34.29%-28.50% Do insiders & institutionals hold more shares of TECX or HLVX? 62.6% of Tectonic Therapeutic shares are owned by institutional investors. Comparatively, 86.4% of HilleVax shares are owned by institutional investors. 38.0% of Tectonic Therapeutic shares are owned by insiders. Comparatively, 24.9% of HilleVax shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media refer more to TECX or HLVX? In the previous week, Tectonic Therapeutic and Tectonic Therapeutic both had 2 articles in the media. Tectonic Therapeutic's average media sentiment score of 1.64 beat HilleVax's score of 0.00 indicating that Tectonic Therapeutic is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tectonic Therapeutic 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive HilleVax 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryTectonic Therapeutic beats HilleVax on 10 of the 13 factors compared between the two stocks. Get HilleVax News Delivered to You Automatically Sign up to receive the latest news and ratings for HLVX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HLVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HLVX vs. The Competition Export to ExcelMetricHilleVaxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$103.29M$3.09B$5.82B$9.74BDividend YieldN/A2.23%3.84%4.09%P/E Ratio-1.4421.1431.1525.97Price / SalesN/A399.83475.57123.18Price / CashN/A43.0937.1558.38Price / Book0.708.079.116.39Net Income-$147.27M-$54.72M$3.26B$265.66M7 Day Performance-0.96%2.62%2.11%1.98%1 Month Performance-2.37%7.63%5.12%1.33%1 Year Performance7.29%13.11%31.25%21.15% HilleVax Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HLVXHilleVax1.6447 of 5 stars$2.06-0.5%$2.00-2.9%+3.5%$103.29MN/A-1.4420TECXTectonic Therapeutic2.7467 of 5 stars$22.14+0.1%$80.33+262.8%+56.3%$413.35MN/A-5.48120Positive NewsEOLSEvolus4.1146 of 5 stars$6.36+10.2%$21.25+234.1%-52.6%$412.21M$266.27M-6.50170CMPSCOMPASS Pathways2.6396 of 5 stars$4.29-1.3%$16.29+280.1%-38.8%$411.01MN/A-2.33120PRTAProthena3.3286 of 5 stars$7.62-0.7%$30.25+297.2%-61.0%$410.45M$135.16M-1.35130REPLReplimune Group4.4479 of 5 stars$5.15+3.1%$7.67+49.0%-45.5%$401.62MN/A-1.59210Gap DownARCTArcturus Therapeutics3.1865 of 5 stars$14.53+27.5%$50.00+244.2%-20.1%$399.61M$152.31M-5.82180Analyst ForecastHigh Trading VolumeRGNXREGENXBIO4.3822 of 5 stars$7.87+5.5%$28.38+260.5%-33.6%$395.75M$83.33M-2.28370Analyst ForecastAnalyst RevisionMBXMBX Biosciences2.6402 of 5 stars$11.79+4.7%$37.63+219.1%N/A$394.07MN/A-2.6036ATXSAstria Therapeutics2.9519 of 5 stars$6.86+2.7%$29.00+322.6%-46.8%$386.26MN/A-3.6630YMABY-mAbs Therapeutics2.1246 of 5 stars$8.52-0.1%$11.16+31.1%-38.4%$385.56M$87.68M-17.03150 Related Companies and Tools Related Companies TECX Competitors EOLS Competitors CMPS Competitors PRTA Competitors REPL Competitors ARCT Competitors RGNX Competitors MBX Competitors ATXS Competitors YMAB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HLVX) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HilleVax, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share HilleVax With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access